Elicio Therapeutics, Inc ELTX 深 滬
等待開盤 06-17 09:30:00 美东时间
2.76
-1.320
-32.35%
華盛通- 最 高4.08
- 今 開4.08
- 成交量 486.65万股
- 最 低 2.66
- 昨 收 4.08
- 總市值 5267.76万
- 52周最高 16.00
- 市盈率 靜 --
- 換手率 25.50%
- 52周最低 2.66
- 委 比 96.26%
- 總股本 1908.61万
- 歷史最高 263.00
- 量 比 2.66
- 振 幅 34.80%
- 歷史最低 2.66
- 每 手 1
- 風險率 1.63%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Jones Trading Downgrades Elicio Therapeutics to Hold
Jones Trading analyst Boris Peaker downgrades Elicio Therapeutics (NASDAQ:ELTX) from Buy to Hold.
今天 00:30
美股大行评级 | 大摩再上调希捷科技和西部数据目标价；多家大行首予Lincoln买入评级
今日重点评级关注：HC Wainwright & Co.：维持Elicio Therapeutics"买入"评级，目标价从17美元升至23美元；Leerink Partners：维持SAB Biotherapeutics"跑赢大市"评级，目标价从7美元升至12美元
06-16 11:34
Elicio Therapeutics Pancreatic Cancer Study Disappoints
Elicio Therapeutics Inc. (NASDAQ:ELTX) stock is trading lower on Monday after disappointing results from its Phase 2 AMPLIFY-7P study of ELI-002 7P in patients with mutant KRAS-driven pancreatic ductal adenocarcinoma (PDAC) following standard locoregional treatment. Elicio Therapeutics Misses Primar...
06-16 00:29
10 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Gelteq (NASDAQ:GELS) shares moved upwards by 50.5% to $1.49 during Monday's pre-market session. The company's market cap stands at $10.6 million. Quantum Cyber (NASDAQ:QUCY) shares moved upwards by 15.58% to $2.0. The market value of their outstanding shares is at $39.3 million. Cypherpunk T...
06-15 20:05
美股大行评级 | 高盛上调美光科技目标价从400美元升至900美元；斯马克、Cloudflare获多家公司上调目标价
今日重点评级关注：Ascendiant Capital：维持NextTrip"买入"评级，目标价从7美元升至7.5美元；Maxim Group：维持Zevra Therapeutics"买入"评级，目标价从25美元升至35美元
06-11 09:55
B. Riley Securities Initiates Coverage On Elicio Therapeutics with Buy Rating, Announces Price Target of $27
B. Riley Securities analyst Mayank Mamtani initiates coverage on Elicio Therapeutics (NASDAQ:ELTX) with a Buy rating and announces Price Target of $27.
06-11 02:07
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
HC Wainwright & Co. Reiterates Buy on Elicio Therapeutics, Maintains $17 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates Elicio Therapeutics (NASDAQ:ELTX) with a Buy and maintains $17 price target.
05-28 18:42
Elicio Therapeutics Q1 EPS $(0.65) Misses $(0.47) Estimate
Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.47) by 41.3 percent. This is a 25.29 percent increase over losses of $(0.87) per share
05-12 04:21
Elicio Therapeutics Launches $100M At-The-Market Offering Program, Replaces Prior $40M Sales Agreement
Entry into a Material Definitive Agreement.On March 16, 2026, Elicio Therapeutics, Inc. (the "Company") entered into an At Market Issuance Sales Agreement (the "Sales Agreement") with B. Riley Securities, Inc.,
03-16 21:29
